CH616135A5 - Process for the preparation of polyene compounds - Google Patents
Process for the preparation of polyene compounds Download PDFInfo
- Publication number
- CH616135A5 CH616135A5 CH171176A CH171176A CH616135A5 CH 616135 A5 CH616135 A5 CH 616135A5 CH 171176 A CH171176 A CH 171176A CH 171176 A CH171176 A CH 171176A CH 616135 A5 CH616135 A5 CH 616135A5
- Authority
- CH
- Switzerland
- Prior art keywords
- acid
- methoxy
- phenyl
- dimethyl
- formula
- Prior art date
Links
- -1 polyene compounds Chemical class 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 11
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 7
- 125000005042 acyloxymethyl group Chemical group 0.000 claims abstract description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 6
- 125000004849 alkoxymethyl group Chemical group 0.000 claims abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000002905 alkanoylamido group Chemical group 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims abstract description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000002431 hydrogen Chemical class 0.000 claims abstract 4
- 239000002253 acid Substances 0.000 claims description 62
- 150000001875 compounds Chemical class 0.000 claims description 20
- 125000004494 ethyl ester group Chemical group 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 150000004820 halides Chemical class 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 125000004970 halomethyl group Chemical group 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 239000007859 condensation product Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000005871 repellent Substances 0.000 claims description 2
- 125000001174 sulfone group Chemical group 0.000 claims description 2
- YULJPXSLWCGOOB-DUXPYHPUSA-N (e)-4-bromo-3-methylbut-2-enoic acid Chemical compound BrCC(/C)=C/C(O)=O YULJPXSLWCGOOB-DUXPYHPUSA-N 0.000 claims 1
- MIOQAXCZXWHELT-UHFFFAOYSA-N 2-methoxy-1,3,4-trimethylbenzene Chemical compound COC1=C(C)C=CC(C)=C1C MIOQAXCZXWHELT-UHFFFAOYSA-N 0.000 claims 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims 1
- 229940073608 benzyl chloride Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 125000003118 aryl group Chemical group 0.000 abstract description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract description 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- JEHKKBHWRAXMCH-UHFFFAOYSA-N benzenesulfinic acid Chemical compound O[S@@](=O)C1=CC=CC=C1 JEHKKBHWRAXMCH-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000155 melt Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012259 ether extract Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 4
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 4
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- OMOVVBIIQSXZSZ-UHFFFAOYSA-N [6-(4-acetyloxy-5,9a-dimethyl-2,7-dioxo-4,5a,6,9-tetrahydro-3h-pyrano[3,4-b]oxepin-5-yl)-5-formyloxy-3-(furan-3-yl)-3a-methyl-7-methylidene-1a,2,3,4,5,6-hexahydroindeno[1,7a-b]oxiren-4-yl] 2-hydroxy-3-methylpentanoate Chemical compound CC12C(OC(=O)C(O)C(C)CC)C(OC=O)C(C3(C)C(CC(=O)OC4(C)COC(=O)CC43)OC(C)=O)C(=C)C32OC3CC1C=1C=COC=1 OMOVVBIIQSXZSZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000003154 papilloma Diseases 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000009121 systemic therapy Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- VMSYOJIGAZHOLW-UHFFFAOYSA-N (4-methoxy-2,3,6-trimethylphenyl)methanol Chemical compound COC1=CC(C)=C(CO)C(C)=C1C VMSYOJIGAZHOLW-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- ZOAMZFNAPHWBEN-UHFFFAOYSA-N 2-$l^{1}-oxidanylpropane Chemical compound CC(C)[O] ZOAMZFNAPHWBEN-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YMDNODNLFSHHCV-UHFFFAOYSA-N 2-chloro-n,n-diethylethanamine Chemical compound CCN(CC)CCCl YMDNODNLFSHHCV-UHFFFAOYSA-N 0.000 description 1
- VSNLEPGWFLVFAU-UHFFFAOYSA-N 3,7-dimethylnona-1,3,5,7-tetraene Chemical compound CC=C(C)C=CC=C(C)C=C VSNLEPGWFLVFAU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PFUKZFFEUQXNRF-UHFFFAOYSA-N 3-methylpyridin-1-ium;chloride Chemical compound [Cl-].CC1=CC=C[NH+]=C1 PFUKZFFEUQXNRF-UHFFFAOYSA-N 0.000 description 1
- BVSUQNWNDYKVET-UHFFFAOYSA-N 4-(chloromethyl)-1-methoxy-2,3,5-trimethylbenzene Chemical compound COC1=CC(C)=C(CCl)C(C)=C1C BVSUQNWNDYKVET-UHFFFAOYSA-N 0.000 description 1
- BSHDRMLUCYMQOP-UHFFFAOYSA-N 4-hydroxy-3-methylbut-2-enal Chemical compound OCC(C)=CC=O BSHDRMLUCYMQOP-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000187 late toxicity Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XUWVIABDWDTJRZ-UHFFFAOYSA-N propan-2-ylazanide Chemical compound CC(C)[NH-] XUWVIABDWDTJRZ-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
- C07C17/12—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms in the ring of aromatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/26—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton
- C07C17/32—Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by introduction of halogenated alkyl groups into ring compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/07—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms
- C07C205/11—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/147—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of carboxylic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
- C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/205—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
- C07C45/515—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups the singly bound functional group being an acetalised, ketalised hemi-acetalised, or hemi-ketalised hydroxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5428—Acyclic unsaturated phosphonium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von neuen Polyenverbindungen. The present invention relates to a process for the preparation of new polyene compounds.
Aus den schweizerischen Patentschriften Nrn. 544 057, 564 504 und 565 735 sind Anhydroretinonsäurederivate mit tumorhemmenden Eigenschaften bekannt. Anhydroretinonic acid derivatives with tumor-inhibiting properties are known from Swiss Patent Nos. 544 057, 564 504 and 565 735.
Ferner sind aus dem J. Chem. Soc. 1958,1855-1861, Retinoide bekannt, welche als cyclische Endgruppe eine Tri-methylphenylgruppe aufweisen und welchen eine wachstumsfördernde, jedoch keine tumorhemmende Wirkung zugeschrieben wird. Furthermore, from J. Chem. Soc. 1958, 1855-1861, known as retinoids which have a tri-methylphenyl group as the cyclic end group and which are attributed to a growth-promoting but not a tumor-inhibiting effect.
Die Aufgabe der Erfindung besteht darin, neue tumorhemmende Wirkstoffe bereitzustellen, welche bezüglich der obengenannten Anhydroretinonsäurederivate fortschrittliche io Eigenschaften, insbesondere ein besseres therapeutisches Verhältnis (die Definition des Begriffes «therapeutisches Verhältnis» ist in J. Cancer 10, 731—33 [1974] gegeben) zeigen. The object of the invention is to provide new tumor-inhibiting active substances which have advanced properties with respect to the above-mentioned anhydroretinonic acid derivatives, in particular a better therapeutic ratio (the definition of the term “therapeutic ratio” is given in J. Cancer 10, 731-33 [1974]). demonstrate.
Die Erfindung betrifft daher ein Verfahren zur Herstellung von Polyenverbindungen der Formel The invention therefore relates to a process for the preparation of polyene compounds of the formula
R, R,
CEL CEL
CIL CIL
, 3 P , 3 P
CH = CH-C - CH-CH = CH-C = CH-R, CH = CH-C - CH-CH = CH-C = CH-R,
in der Ra und R2 niederes Alkyl bedeuten, R3, R4 und R5 Wasserstoff, niederes Alkyl, niederes Alkoxy, niederes Alken-oxy, Nitro, Amino, niederes Alkanoylamido oder einen N-heterocyclischen Rest darstellen, wobei mindestens einer der Reste R3 bis Rs von Wasserstoff verschieden ist und wobei, wenn einer der Reste R3, R4 und Rs niederes Alkyl bedeutet, die beiden anderen nicht Wasserstoff bedeuten, und R6 Formyl, Alkoxymethyl, Alkanoyloxymethyl, Carboxyl, Alkoxycarbonyl, di-nieder-Alkylcarbamoyl oder N-Hetero-cyclylcarbonyl bedeutet. in which Ra and R2 are lower alkyl, R3, R4 and R5 are hydrogen, lower alkyl, lower alkoxy, lower alkene oxy, nitro, amino, lower alkanoylamido or an N-heterocyclic radical, where at least one of the radicals R3 to Rs is from Hydrogen is different and where, if one of the radicals R3, R4 and Rs is lower alkyl, the other two are not hydrogen, and R6 is formyl, alkoxymethyl, alkanoyloxymethyl, carboxyl, alkoxycarbonyl, di-lower alkylcarbamoyl or N-heterocyclocarbonyl .
Die vorstehend genannten niederen Alkylgruppen enthalten vornehmlich bis zu 6 Kohlenstoffatome, wie die Methyl-, Äthyl-, Propyl-, Isopropyl- oder 2-Methylpropylgruppe. Die niederen Alkoxy- und niederen Alkenoxygruppen enthalten ebenfalls vornehmlich bis zu 6 Kohlenstoffatome, wie die Methoxy-, Äthoxy- oder Isopropoxygruppe und die Vinyloxy-oder Allyloxygruppe. The above-mentioned lower alkyl groups mainly contain up to 6 carbon atoms, such as the methyl, ethyl, propyl, isopropyl or 2-methylpropyl group. The lower alkoxy and lower alkenoxy groups also primarily contain up to 6 carbon atoms, such as the methoxy, ethoxy or isopropoxy group and the vinyloxy or allyloxy group.
Die niederen Alkanoylamidogruppen enthalten Reste, die sich von niederen Alkancarbonsäuren mit bis zu 6 Kohlenstoffatomen, z. B. von der Essig-, Propion- oder Pivalinsäure, ableiten. The lower alkanoylamido groups contain residues which are different from lower alkane carboxylic acids with up to 6 carbon atoms, e.g. B. derived from acetic, propionic or pivalic acid.
Die N-Heterocyclylreste sind vornehmlich 5- oder 6glied-rige Reste, die gegebenenfalls neben dem Stickstoffatom als weiteres Heteroatom Sauerstoff, Stickstoff oder Schwefel enthalten. Beispiele hierfür sind der Pyrrolidino-, Piperidino-, Morpholino- oder Thiomorpholinorest. Beispiele für mono-oder di-nieder-Alkylcarbamoyl sind Methylcarbamoyl, Dimethylcarbamoyl und Diäthylcarbamoyl. The N-heterocyclyl radicals are primarily 5- or 6-membered radicals which optionally contain oxygen, nitrogen or sulfur as a further heteroatom in addition to the nitrogen atom. Examples of this are the pyrrolidino, piperidino, morpholino or thiomorpholino radical. Examples of mono- or di-lower alkylcarbamoyl are methylcarbamoyl, dimethylcarbamoyl and diethylcarbamoyl.
Die weiterhin genannten Alkoxymethyl- und Alkoxy-carbonylgruppen enthalten vornehmlich Alkoxyreste mit bis zu 6 Kohlenstoffatomen. Diese können verzweigt oder unverzweigt sein, wie beispielsweise der Methoxy-, Äthoxy- oder Isopropoxyrest. Darüber hinaus kommen aber auch höhere Alkoxyreste mit 7 bis 20 Kohlenstoffatomen, von diesen insbesondere der Cetyloxyrest, in Frage. The alkoxymethyl and alkoxycarbonyl groups mentioned above contain mainly alkoxy radicals with up to 6 carbon atoms. These can be branched or unbranched, for example the methoxy, ethoxy or isopropoxy radical. In addition, however, higher alkoxy radicals with 7 to 20 carbon atoms, of which in particular the cetyloxy radical, are also suitable.
Die Alkanoyloxymethylgruppen leiten sich vornehmlich von niederen Alkancarbonsäuren mit 1 bis 6 Kohlenstoffatomen, z. B. von der Essig-, Propion- oder Pivalinsäure, gegebenenfalls aber auch von höheren Alkancarbonsäuren mit 7 bis 20 Kohlenstoffatomen, z. B. von der Palmitin- oder Stearinsäure, ab. The alkanoyloxymethyl groups are primarily derived from lower alkane carboxylic acids having 1 to 6 carbon atoms, e.g. B. of acetic, propionic or pivalic acid, but optionally also of higher alkane carboxylic acids with 7 to 20 carbon atoms, for. B. from palmitic or stearic acid.
Die N-Heterocyclylreste der N-Heterocyclylcarbonyl-gruppen sind vornehmlich 5- oder 6gliedrig heterocyclische Reste, die gegebenenfalls neben dem Stickstoffatom, Sauer-30 Stoff, Stickstoff oder Schwefel als weiteres Heteroatom enthalten. Beispiele hierfür sind der Piperidino-, Morpholino-, Thiomorpholino- oder Pyrrolidinorest. The N-heterocyclyl radicals of the N-heterocyclylcarbonyl groups are predominantly 5- or 6-membered heterocyclic radicals which, in addition to the nitrogen atom, contain acid, nitrogen or sulfur as a further heteroatom. Examples include the piperidino, morpholino, thiomorpholino or pyrrolidino radical.
Vorzugsweise werden all-trans-Verbindungen hergestellt. Wenn im folgenden spezifisch genannte Verbindungen der 35 Formeln I, II oder III angegeben sind, so sind darunter stets all-trans-Verbindungen zu verstehen, sofern nicht ein besonderer Hinweis auf eine cis-Verbindung oder ein cis/trans-Gemisch existiert. All-trans connections are preferably produced. If specifically named compounds of the formulas I, II or III are given below, they are always to be understood as all-trans compounds, unless there is a special reference to a cis compound or a cis / trans mixture.
Als repräsentativer Vertreter der erfindungsgemäss her-40 stellbaren Verbindungsklasse können genannt werden: 9-(2,3,4,6-Tetramethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8- The following can be mentioned as representative representatives of the class of compounds which can be prepared according to the invention: 9- (2,3,4,6-tetramethylphenyl) -3,7-dimethyl-nona-2,4,6,8-
tetraen-l-säure, 9-(4-Methoxy-2,6-dimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure, 45 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure, 9-(3-Methoxy-2,4,6-trimethyl-phenyl)-3,7-dimethyl-nona- tetraen-l-acid, 9- (4-methoxy-2,6-dimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid, 45 9- (4- Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid, 9- (3-methoxy-2,4,6-trimethyl- phenyl) -3,7-dimethyl-nona-
2,4,6,8-tetraen-l-säure, 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-50 2,4,6,8-tetraen-l-säureäthylester, 2,4,6,8-tetraen-l-acid, 9- (4-methoxy-2,3,6-trimethylphenyl) -3,7-dimethyl-nona-50 2,4,6,8-tetraen -l-acid ethyl ester,
9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2-trans,4-cis,6-trans-8-trans-tetraen-l-säureäthylester, 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säureisopropylester, 55 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure-(diäthylamino)-äthylester, 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona- 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2-trans, 4-cis, 6-trans-8-trans-tetraen-l-acidic acid ethyl ester, 9- (4-Methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acidic acid isopropyl ester, 55 9- (4-methoxy-2,3, 6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid- (diethylamino) -ethyl ester, 9- (4-methoxy-2,3,6-trimethyl- phenyl) -3,7-dimethyl-nona-
2,4,6,8 -tetraen-1 -säureamid, 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-60 2,4,6,8-tetraen-l-säureäthylamid, 2,4,6,8-tetraen-1-acid amide, 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-60 2,4,6,8-tetraene -l-acid ethylamide,
9-(4-Methoxy-3-nitro-2,6-dimethyl-phenyl)-3,7-dimethyl- 9- (4-methoxy-3-nitro-2,6-dimethylphenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure-äthylester, 9-(4-Isopropoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure, 65 9- (4-Allyloxy-2,3,6-trimethyl-pheny 1) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure, 9-(3-Nitro-2,4,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1 -säure. ethyl nona-2,4,6,8-tetraen-1-acid, 9- (4-isopropoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6, 8-tetraen-l-acid, 65 9- (4-allyloxy-2,3,6-trimethylpheny 1) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid, 9- (3-Nitro-2,4,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-1-acid.
616135 4 616 135 4
Das erfindungsgemässe Verfahren ist dadurch gekennzeichnet, dass man eine Verbindung der Formel The process according to the invention is characterized in that a compound of the formula
R, R,
CEL CEL
I ^ I ^
CH = CH - C = CH CH = CH - C = CH
(II) (II)
m mit einer Verbindung der allgemeinen Formel m with a compound of the general formula
CH. CH.
B - C = CH B - C = CH
CH. CH.
CH = CH - C = CH CH = CH - C = CH
R, R,
7 7
(III) (III)
n in denen m = 0 und n = 1, oder m = 1 und n = 0 sind, eines der beiden Symbole A und B eine Sulfonylmethylgruppe der Formel —CH2S02E, worin E einen gegebenenfalls durch eine oder mehrere Elektronen abstossende bis Elektronen schwach anziehende Gruppen substituierten Aryl- oder Aralkenyl-rest darstellt und das andere Symbol Halogenmethyl, Alkyl-sulfonyloxymethyl oder Arylsulfonyloxymethyl bedeutet, die Reste Ri, R2, R3, R4 und Rs die oben angegebene Bedeutung haben, und R7 Carboxy, Alkoxycarbonyl, di-nieder-Alkyl-carbamoyl oder N-Heterocyclylcarbonyl bedeutet und R7, n in which m = 0 and n = 1, or m = 1 and n = 0, one of the two symbols A and B is a sulfonylmethyl group of the formula —CH2S02E, in which E is a group which is optionally repelled by one or more electrons or weakly attracting to electrons represents substituted aryl or aralkenyl radical and the other symbol means halomethyl, alkylsulfonyloxymethyl or arylsulfonyloxymethyl, the radicals Ri, R2, R3, R4 and Rs have the meaning given above, and R7 carboxy, alkoxycarbonyl, di-lower alkyl means carbamoyl or N-heterocyclylcarbonyl and R7,
falls B Halogenmethyl, Alkylsulfonyloxymethyl oder Arylsulfonyloxymethyl darstellt, zusätzlich Formyl, Alkoxymethyl und Alkanoyloxymethyl; und R7, falls B eine Sulfonylmethylgruppe darstellt, zusätzlich Formyl bedeutet, umsetzt und die im Kondensationsprodukt vorhandene Sulfongruppe unter Ausbildung einer zusätzlichen Kohlenstoff-Kohlenstoff-Bindung abspaltet. if B represents halomethyl, alkylsulfonyloxymethyl or arylsulfonyloxymethyl, additionally formyl, alkoxymethyl and alkanoyloxymethyl; and R7, if B represents a sulfonylmethyl group, additionally means formyl, and the sulfone group present in the condensation product is split off with the formation of an additional carbon-carbon bond.
Als Beispiele für die in der Sulfonylmethylgruppe der Formel —CH2S02E mit E bezeichneten, gegebenenfalls durch eine oder mehrere Elektronen abstossende bis Elektronen schwach anziehende Gruppen substituierten Aryl- oder Aral-kenylreste können genannt werden: Phenyl und Styryl, beide Reste in o-, m- oder p-Stellung gegebenenfalls substituiert durch Examples of the aryl or aralkenyl radicals which are designated by E in the sulfonylmethyl group of the formula —CH2S02E and are optionally substituted by one or more electron-repelling to electron-attracting groups are: phenyl and styryl, both radicals in o-, m- or p-position optionally substituted by
— Methoxy, Phenoxy, Acetoxy; - methoxy, phenoxy, acetoxy;
— Dimethylamino, Phenylmethylamino, Acetylamino; - dimethylamino, phenylmethylamino, acetylamino;
- Thiomethyl, Thiophenyl, Thioacetyl; - thiomethyl, thiophenyl, thioacetyl;
- Chlor, Brom; - chlorine, bromine;
- Cyan; oder - cyan; or
— Nitro in m-Stellung. - Nitro in the m position.
Die Ausgangssubstanzen der Formeln II und III sind zum Teil neue Verbindungen. Sie sind z. B. auf folgendem Wege erhältlich: Some of the starting substances of formulas II and III are new compounds. You are e.g. B. Available in the following ways:
Verbindungen der Formel He, in der m = 0 ist und A eine Sulfonylmethylgruppe bedeutet, können z. B. dadurch hergestellt werden, dass man einen durch die Reste Rj-Rs-substi-tuierten Benzylalkohol oder ein entsprechendes Benzyl-halogenid in einem polaren Lösungsmittel, z. B. in einem Alkanol wie Methanol, Äthanol oder Isopropanol, oder in Tetrahydrofuran oder Dimethylformamid, oder auch in Eisessig löst und bei Raumtemperatur mit einer Sulfinsäure der Compounds of the formula He in which m = 0 and A denotes a sulfonylmethyl group can, for. B. be prepared by using a benzyl alcohol substituted by the Rj-Rs radicals or a corresponding benzyl halide in a polar solvent, e.g. B. in an alkanol such as methanol, ethanol or isopropanol, or in tetrahydrofuran or dimethylformamide, or also in glacial acetic acid and at room temperature with a sulfinic acid
Formel ^q_ S-E, in der E einen gegebenenfalls durch eine Formula ^ q_ S-E, in which E may be a by
25 oder mehrere Elektronen abstossende oder Elektronen schwach anziehende Gruppe substituierten Aryl- oder Aralkenyl-rest darstellt, oder mit einem Alkalisalz dieser Sulfinsäure umsetzt. Das Sulfon kann aus dem Reaktionsgemisch z. B. in der Weise isoliert werden, dass man die Reaktionslösung durch 30 Zugabe einer wässrigen Natriumhydrogencarbonatlösung neutral stellt und das Sulfon mit einem organischen Lösungsmittel, z. B. mit Essigsäureäthylester oder Äther, extrahiert. 25 or more electron-repellent or electron-attracting group substituted aryl or aralkenyl radical, or reacted with an alkali salt of this sulfinic acid. The sulfone can z. B. be isolated in such a way that the reaction solution is neutralized by adding an aqueous sodium hydrogen carbonate solution and the sulfone with an organic solvent, for. B. extracted with ethyl acetate or ether.
Verbindungen der Formel Ilf, in der m = 1 ist und A eine Sulfonylmethylgruppe bedeutet, sind in analoger Weise durch 35 Umsetzen eines durch die Reste Rj—R5-substituierten Phenyl-3-methyl-penta-2,4-dien-l-oIs oder eines Halogenids dieses Alkohols mit der vorstehend beschriebenen Sulfinsäure oder mit einem Alkalimetallsalz dieser Säure erhältlich. Compounds of the formula IIf in which m = 1 and A denotes a sulfonylmethyl group are obtained in an analogous manner by reacting a phenyl-3-methyl-penta-2,4-diene-1-oIs substituted by the radicals Rj — R5 or a halide of this alcohol with the sulfinic acid described above or with an alkali metal salt of this acid.
Auch die Verbindungen der Formel III sind zum Teil neu: 40 Verbindungen der Formel Ille, in der n = 0 ist und B eine Sulfonylmethylgruppe bedeutet, lassen sich z. B. in der Weise darstellen, dass man 4-Hydroxy-3-methyl-but-2-en-l-al oder das Acelat oder Bromid dieses Alkohols in einem polaren Lösungsmittel, z. B. in Isopropanol oder n-Butanol, wie vor-45 stehend beschrieben mit der oben definierten Sulfinsäure oder mit einem Alkalimetallsalz dieser Säure umsetzt. Some of the compounds of the formula III are new: 40 compounds of the formula III, in which n = 0 and B is a sulfonylmethyl group, can be, for. B. represent in such a way that 4-hydroxy-3-methyl-but-2-en-l-al or the acelate or bromide of this alcohol in a polar solvent, for. B. in isopropanol or n-butanol, as described above with the sulfinic acid defined above or with an alkali metal salt of this acid.
Verbindungen der Formel Ulf, in der n = 1 ist und B eine Sulfonylmethylgruppe bedeutet, lassen sich in analoger Weise, wie vorstehend beschrieben, durch Umsetzen von beispiels-50 weise 8-Hydroxy-3,7-dimethyl-octa-2,4,6-trien-l-säure oder dem Acetat oder Bromid dieses Alkohols mit der oben definierten Sulfinsäure herstellen. Compounds of the formula Ulf, in which n = 1 and B denotes a sulfonylmethyl group, can be prepared in an analogous manner, as described above, by reacting 8-hydroxy-3,7-dimethyl-octa-2,4, for example, Prepare 6-triene-l-acid or the acetate or bromide of this alcohol with the sulfinic acid defined above.
Gemäss der Erfindung werden: According to the invention:
55 — Sulfone der Formel Ile oder Ilf mit Halogeniden der Formel Ulk oder Uli oder 55 - Sulfones of the formula Ile or Ilf with halides of the formula Ulk or Uli or
- Sulfone der Formel Ille oder Illf mit Halogeniden der Formel Ilk oder Iii - Sulphones of the formula Ille or Illf with halides of the formula Ilk or Iii
60 umgesetzt. 60 implemented.
Nach der von Julia angegebenen Arbeitsweise werden die Komponenten mit Hilfe eines Kondensationsmittels zweckmässig in Gegenwart eines polaren Lösungsmittels mitein-65 ander verknüpft. Als Lösungsmittel geeignet sind z. B. Dimethylformamid, Dimethylsulfoxyd, Dimethylacetamid, Tetrahydrofuran und Hexamethylphosphorsäuretriamid, sowie ferner Alkanole, wie Methanol, Isopropanol oder tert.-ButanoI. According to the method of operation specified by Julia, the components are expediently linked to one another with the aid of a condensing agent in the presence of a polar solvent. Suitable solvents are, for. B. dimethylformamide, dimethyl sulfoxide, dimethylacetamide, tetrahydrofuran and hexamethylphosphoric triamide, and also alkanols, such as methanol, isopropanol or tert-butanol.
5 5
616 135 616 135
Von den als Kondensationsmittel in Frage kommenden vornehmlich starken Basen können beispielsweise genannt werden: Alkali- und Erdalkali-carbonate, insbesondere Natrium-carbonat; Alkalimetallhydroxyde wie Kalium- oder Natriumhydroxyd; Alkali- und Erdalkalialkoholate wie Natrium-methylat und insbesondere Kalium-tert.-butylat; Alkalimetallhydride wie Natriumhydrid; Alkylmagnesiumhalogenide wie Methylmagnesiumbromid; sowie ferner auch Alkali-metallamide wie Natriumamid. Die Verknüpfung wird vorzugsweise bei niederen Temperaturen, insbesondere bei Temperaturen unterhalb des Gefrierpunktes, z. B. in einem zwischen -50 und -80° C liegenden Temperaturbereich, durchgeführt. Of the predominantly strong bases that are suitable as condensing agents, examples may be mentioned: alkali and alkaline earth carbonates, in particular sodium carbonate; Alkali metal hydroxides such as potassium or sodium hydroxide; Alkali and alkaline earth alcoholates such as sodium methylate and especially potassium tert-butoxide; Alkali metal hydrides such as sodium hydride; Alkyl magnesium halides such as methyl magnesium bromide; and also also alkali metal amides such as sodium amide. The linkage is preferably at low temperatures, especially at temperatures below freezing, e.g. B. in a temperature range between -50 and -80 ° C, performed.
Es hat sich in bestimmten Fällen als zweckmässig erwiesen, die vorstehend genannten Reaktionen in situ, d. h. die Kondensationskomponenten ohne das betreffende Sulfon zu isolieren, miteinander zu verknüpfen. In certain cases, it has proven to be expedient to carry out the above-mentioned reactions in situ, i. H. to link the condensation components without isolating the sulfone in question.
Eine Carbonsäure der Formel I kann in an sich bekannter Weise, z. B. durch Behandeln mit Thionylchlorid, vorzugsweise in Pyridin, in das Säurechlorid übergeführt werden, das durch Umsetzen mit einem Alkanol in einen Ester, mit Ammoniak in das Amid umgewandelt werden kann. A carboxylic acid of the formula I can be prepared in a manner known per se, e.g. B. by treatment with thionyl chloride, preferably in pyridine, be converted into the acid chloride, which can be converted into the amide with ammonia by reaction with an alkanol into an ester.
Ein Carbonsäureester der Formel I kann in an sich bekannter Weise, z. B. durch Behandeln mit Alkalien, insbesondere durch Behandeln mit wässriger alkoholischer Natronoder Kalilauge in einem zwischen der Raumtemperatur und dem Siedepunkt des Reaktionsgemisches liegenden Temperaturbereich hydrolysiert und entweder über ein Säurehalo-genid oder, wie nachstehend beschrieben, unmittelbar ami-diert werden. A carboxylic acid ester of the formula I can be prepared in a manner known per se, e.g. B. hydrolyzed by treatment with alkalis, in particular by treatment with aqueous alcoholic sodium or potassium hydroxide in a temperature range between room temperature and the boiling point of the reaction mixture and either amidated with an acid halide or, as described below, directly amidated.
Ein Carbonsäureester der Formel I kann z. B. durch Behandeln mit Lithiumamid direkt in das entsprechende Amid umgewandelt werden. Das Lithiumamid wird vorteilhaft bei Raumtemperatur mit dem betreffenden Ester zur Reaktion gebracht. A carboxylic acid ester of formula I can e.g. B. be converted directly into the corresponding amide by treatment with lithium amide. The lithium amide is advantageously reacted with the ester in question at room temperature.
Ein Amin der Formel I bildet mit anorganischen oder organischen Säuren Additionssalze. Als Beispiele können genannt werden: Salze mit Halogenwasserstoffsäuren, insbesondere mit der Chlor- oder Bromwasserstoffsäure, Salze mit Mineralsäuren, z. B. mit Schwefelsäure, oder auch Salze mit organischen Säuren, z. B. mit der Benzoesäure, Essigsäure, Zitronensäure oder Milchsäure. An amine of the formula I forms addition salts with inorganic or organic acids. Examples include: salts with hydrohalic acids, especially with hydrochloric or hydrobromic acid, salts with mineral acids, e.g. B. with sulfuric acid, or salts with organic acids, for. B. with benzoic acid, acetic acid, citric acid or lactic acid.
Eine Carbonsäure der Formel I bildet mit Basen, insbesondere mit den Alkalimetallhydroxyden, vorzugsweise mit Natrium- oder Kaliumhydroxyd Salze. A carboxylic acid of the formula I forms salts with bases, in particular with the alkali metal hydroxides, preferably with sodium or potassium hydroxide.
Die Verbindungen der Formel I können als cis/trans-Gemische anfallen, welche in an sich bekannter Weise er-wünschtenfalls in die eis- und trans-Komponenten aufgetrennt oder zu den all-trans-Verbindungen isomerisiert werden können. The compounds of the formula I can be obtained as cis / trans mixtures which, if desired, can be separated into the ice and trans components or isomerized to the all-trans compounds if desired.
Die Verfahrensprodukte der Formel I stellen pharmako-dynamisch wertvolle Verbindungen dar. Sie können zur topischen und systemischen Therapie von benignen und malignen Neoplasien, von prämalignen Läsionen sowie ferner auch zur systemischen und topischen Prophylaxe der genannten Affektionen verwendet werden. Sie sind des weiteren für die topische und systemische Therapie von Akne, Psoriasis und anderen mit einer verstärkten oder pathologisch veränderten Verhornung einhergehenden Dermatosen, wie auch von entzündlichen und allergischen dermatologischen Affektionen geeignet. Die Verfahrensprodukte der Formel I können ferner auch zur Bekämpfung von Schleimhauterkrankungen mit entzündlichen-oder degenerativen bzw. metaplastischen Veränderungen eingesetzt werden. The process products of formula I are pharmaco-dynamically valuable compounds. They can be used for topical and systemic therapy of benign and malignant neoplasms, of premalignant lesions and also for systemic and topical prophylaxis of the above-mentioned affections. They are also suitable for topical and systemic therapy of acne, psoriasis and other dermatoses associated with increased or pathologically altered cornification, as well as for inflammatory and allergic dermatological affections. The process products of the formula I can also be used to combat mucosal diseases with inflammatory or degenerative or metaplastic changes.
Die Toxizität der neuen Verbindungsklasse ist gering. Die akute Toxizität [DLS0] der 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure[A] und des 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- The toxicity of the new class of compounds is low. The acute toxicity [DLS0] of 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid [A] and des 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säureäthyl-esters[B] z. B. liegt —wie aus der in der nachstehenden Tabelle verzeichneten Spät-toxizität nach 20 Tagen ersichtlich — bei der Maus nach intraperitonealer Verabreichung in Rüböl bei 700 bzw. 1000 mg/kg. nona-2,4,6,8-tetraen-l-acid ethyl ester [B] z. B. - as can be seen from the late toxicity after 20 days shown in the table below - in the mouse after intraperitoneal administration in rapeseed oil it was 700 or 1000 mg / kg.
Akute Toxizität Substanz A Acute toxicity substance A
DL10 mg/kg DL10 mg / kg
DLso mg/kg DLso mg / kg
DL90 mg/kg nach 1 Tag DL90 mg / kg after 1 day
>4000 > 4000
>4000 > 4000
>4000 > 4000
nach 10 Tagen after 10 days
580 580
700 700
890 890
nach 20 Tagen after 20 days
580 580
700 700
890 890
Akute Toxizität Substanz B Acute toxicity substance B
o r e o r e
3 3rd
CTQ CTQ
ero ero
DLso mg/kg DLso mg / kg
DL90 mg/kg nach 1 Tag >4000 >4000 >4000 DL90 mg / kg after 1 day> 4000> 4000> 4000
nach 10 Tagen 1400 1900 2600 after 10 days 1400 1900 2600
nach 20 Tagen 710 1000 1400 after 20 days 710 1000 1400
Die tumorhemmende Wirkung der Verfahrensprodukte ist signifikant. Im Papillomtest regressieren mit Dimethylbenz-anthracen und Krotonöl induzierte Tumoren. Die Durchmesser der Papillome nehmen innerhalb von 2 Wochen bei intraperitonealer Applikation von Substanz A: bei 50 mg/kg/Woche um 38% The tumor-inhibiting effect of the process products is significant. In the papilloma test, tumors induced with dimethylbenzanthracene and croton oil regress. The diameters of the papillomas increase within 2 weeks with intraperitoneal application of substance A: at 50 mg / kg / week by 38%
bei 100 mg/kg/Woche um 69% von Substanz B : bei 25 mg/kg/Woche um 45 % bei 50 mg/kg/Woche um 63 % at 100 mg / kg / week by 69% of substance B: at 25 mg / kg / week by 45% at 50 mg / kg / week by 63%
ab. from.
Die Verbindungen der Formel I können deshalb als Heilmittel, z. B. in Form pharmazeutischer Präparate, Anwendung finden. The compounds of formula I can therefore be used as medicines, e.g. B. in the form of pharmaceutical preparations.
Die zur systemischen Anwendung dienenden Präparate können z. B. dadurch hergestellt werden, dass man eine Verbindung der Formel I als wirksamen Bestandteil nichttoxischen, inerten an sich in solchen Präparaten üblichen festen oder flüssigen Trägern zufügt. The preparations used for systemic use can, for. B. be prepared by adding a compound of formula I as an active ingredient non-toxic, inert solid or liquid carriers which are conventional in such preparations.
Die Mittel können enterai oder parenteral verabreicht werden. Für die enterale Applikation eignen sich z. B. Mittel in Form von Tabletten, Kapseln, Dragées, Sirupen, Suspensionen, Lösungen und Suppositorien. Für die parenterale Applikation sind Mittel in Form von Infusions- oder Injektionslösungen geeignet. The agents can be administered enterally or parenterally. For enteral application z. B. Agents in the form of tablets, capsules, dragées, syrups, suspensions, solutions and suppositories. Agents in the form of infusion or injection solutions are suitable for parenteral administration.
Die Dosierungen, in denen die Verfahrensprodukte verabreicht werden, können je nach Anwendungsart und Anwendungsweg sowie nach den Bedürfnissen der Patienten variieren. The dosages in which the process products are administered can vary depending on the type of application and route of use and on the needs of the patients.
Die Verfahrensprodukte können in Mengen von 5 bis 200 mg täglich in einer oder mehreren Dosierungen verabreicht werden. Eine bevorzugte Darreichungsform sind Kapseln mit einem Gehalt von ca. 10 mg bis ca. 100 mg Wirkstoff. The process products can be administered in amounts of 5 to 200 mg daily in one or more doses. A preferred dosage form are capsules with a content of about 10 mg to about 100 mg of active ingredient.
Die Präparate können inerte oder auch pharmakodyna-misch aktive Zusätze enthalten. Tabletten oder Granula z. B. können eine Reihe von Bindemitteln, Füllstoffen, Trägersubstanzen oder Verdünnungsmitteln enthalten. Flüssige Präparate können beispielsweise in Form einer sterilen, mit Wasser mischbaren Lösung vorliegen. Kapseln können neben dem Wirkstoff zusätzlich ein Füllmaterial oder Verdickungsmittel enthalten. Des weiteren können geschmacksverbessernde Zusätze, sowie die üblicherweise als Konservierungs-, Stabili-sierungs-, Feuchthalte- oder Emulgiermittel verwendeten Stoffe, ferner auch Salze zur Veränderung des osmotischen Druckes, Puffer und andere Zusätze vorhanden sein. The preparations can contain inert or pharmacodynamically active additives. Tablets or granules e.g. B. can contain a number of binders, fillers, carriers or diluents. Liquid preparations can, for example, be in the form of a sterile, water-miscible solution. In addition to the active ingredient, capsules can also contain a filler or thickener. Furthermore, taste-improving additives, as well as the substances usually used as preservatives, stabilizers, moisturizers or emulsifiers, as well as salts for changing the osmotic pressure, buffers and other additives can also be present.
Die vorstehend erwähnten Trägersubstanzen und Verdünnungsmittel können aus organischen oder anorganischen Stoffen, z. B. aus Wasser, Gelatine, Milchzucker, Stärke, The above-mentioned carriers and diluents can be made from organic or inorganic substances, e.g. B. from water, gelatin, milk sugar, starch,
5 5
10 10th
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
50 50
55 55
60 60
65 65
616 135 616 135
6 6
Magnesiumstearat, Talkum, Gummi arabicum, Polyalkylen-glykolen u. dgl. bestehen. Voraussetzung ist, dass alle bei der Herstellung der Präparate verwendeten Hilfsstoffe untoxisch sind. Magnesium stearate, talc, gum arabic, polyalkylene glycols u. Like exist. The prerequisite is that all auxiliary substances used in the manufacture of the preparations are non-toxic.
Zur topischen Anwendung werden die Verfahrensprodukte zweckmässig in Form von Salben, Tinkturen, Cremen, Lösungen, Lotionen, Sprays, Suspensionen u. dgl. verwendet. Bevorzugt sind Salben und Cremen sowie Lösungen. Diese zur topischen Anwendung bestimmten Präparate können dadurch hergestellt werden, dass man die Verfahrensprodukte als wirksamen Bestandteil nichttoxischen, inerten, für topische Behandlung geeigneten, an sich in solchen Präparaten üblichen festen oder flüssigen Trägern zumischt. For topical use, the process products are expediently in the form of ointments, tinctures, creams, solutions, lotions, sprays, suspensions and the like. Like. Used. Ointments and creams and solutions are preferred. These preparations intended for topical use can be prepared by admixing the process products as an effective component of non-toxic, inert, solid or liquid carriers which are customary in such preparations and are suitable for topical treatment.
Für die topische Anwendung sind zweckmässig ca. 0,01-bis ca. 0,3 %ige, vorzugsweise 0,02- bis 0,1 %ige, Lösungen sowie ca. 0,05 bis ca. 5%ige, vorzugsweise ca. 0,1- bis ca. 2,0%ige, Salben oder Cremen geeignet. For topical use, approximately 0.01 to approximately 0.3%, preferably 0.02 to 0.1%, solutions and approximately 0.05 to approximately 5%, preferably approximately 0.1 to approx. 2.0%, ointments or creams suitable.
Den Präparaten kann gegebenenfalls ein Antioxydationsmittel, z. B. Tocopherol, N-Methyl-y-tocopheramin sowie butyliertes Hydroxyanisol oder butyliertes Hydroxytoluol beigemischt sein. The preparations can optionally contain an antioxidant, e.g. B. tocopherol, N-methyl-y-tocopheramine and butylated hydroxyanisole or butylated hydroxytoluene.
Beispiel 1 example 1
A. 2 g l-(Phenyl-sulfonyl)-methyl-4-methoxy-2,3,6-tri-methyl-benzol werden in 10 ml Tetrahydrofuran gelöst. Die Lösung wird auf—78° C gekühlt und nach Zugabe von 0,51 g Butyllithium mit einer Lösung von 1,8 g 8-Brom-3,7-dimethyl-octa-2,4,6-trien-l-säureäthylester in 8 ml Tetrahydrofuran versetzt. Das Reaktionsgemisch wird 2 Stunden bei —78° C, A. 2 g of l- (phenylsulfonyl) methyl-4-methoxy-2,3,6-tri-methyl-benzene are dissolved in 10 ml of tetrahydrofuran. The solution is cooled to -78 ° C. and, after adding 0.51 g of butyllithium, with a solution of 1.8 g of 8-bromo-3,7-dimethyl-octa-2,4,6-triene-l-acidic acid ethyl ester in 8 ml of tetrahydrofuran were added. The reaction mixture is 2 hours at -78 ° C,
2 weitere Stunden bei —40° C und anschliessend 16 Stunden bei 0 bis +5° C gerührt. Das Gemisch wird danach auf Eis gegossen und nach Zugabe von 2n Salzsäure mit Äther extrahiert. Der Ätherextrakt wird mit Wasser neutral gewaschen, über Natriumsulfat getrocknet und unter vermindertem Druck eingedampft. Der zurückbleibende 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-9-(phenyl-sulfonyl)-3,7-dimethyl-nona-2,4,6-trien-l-säureäthylester (2,8 g) wird in 8 ml abs. Äthanol gelöst. Die Lösung wird bei 0° C in 2 Portionen mit insgesamt 1,2 kg Natriumäthylatpulver versetzt. Das Gemisch wird zunächst 30 Minuten bei 0° C, dann 2 Stunden bei 80° C gerührt, danach abgekühlt, auf Eis gegossen und nach Zugabe von 2n Salzsäure mit Äther extrahiert. Der Ätherextrakt wird mit Wasser neutral gewaschen, über Natriumsulfat getrocknet und unter vermindertem Druck eingedampft. Der zurückbleibende 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säureäthylester schmilzt bei 104—105° C. 2 additional hours at -40 ° C and then 16 hours at 0 to + 5 ° C. The mixture is then poured onto ice and extracted with ether after the addition of 2N hydrochloric acid. The ether extract is washed neutral with water, dried over sodium sulfate and evaporated under reduced pressure. The remaining 9- (4-methoxy-2,3,6-trimethyl-phenyl) -9- (phenylsulfonyl) -3,7-dimethyl-nona-2,4,6-triene-l-acidic acid ethyl ester (2, 8 g) is abs in 8 ml. Dissolved ethanol. The solution is mixed at 0 ° C. in 2 portions with a total of 1.2 kg of sodium ethylate powder. The mixture is first stirred at 0 ° C. for 30 minutes, then at 80 ° C. for 2 hours, then cooled, poured onto ice and, after addition of 2N hydrochloric acid, extracted with ether. The ether extract is washed neutral with water, dried over sodium sulfate and evaporated under reduced pressure. The remaining 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acidic acid ester melts at 104-105 ° C.
Das als Ausgangsverbindung eingesetzte l-(Phenyl-sulphonyl)-methyl-4-methoxy-2,3,6-trimethyl-benzol kann z. B. wie folgt hergestellt werden: The l- (phenylsulfonyl) methyl-4-methoxy-2,3,6-trimethyl-benzene used as the starting compound can be e.g. B. can be produced as follows:
16,8 g 4-Methoxy-2,3,6-trimethyl-benzylalkohol 17,4 g Na-Salz der Benzolsulfinsäure, 20,0 ml Isopropanol und 30,0 ml Eisessig werden in einer Stickstoffatmosphäre 16 Stunden unter Rückfluss erhitzt. Das Reaktionsgemisch wird nach dem Erkalten portionenweise mit 200 ml Wasser versetzt und durch Zugabe von Natriumhydrogencarbonat neutralisiert. Die organische Phase wird abgetrennt, mehrmals mit einer 5 %igen wässerigen Natriumhydrogencarbonatlösung gewaschen, über Natriumsulfat getrocknet und unter vermindertem Druck eingedampft. Das zurückbleibende l-(Phenyl-sulfonyl)-methyl-4-methoxy-2,3,6-trimethylbenzol zeigt folgende I—R-Banden: 1592, 1580, 1302, 1149, 1118 cm-1. 16.8 g of 4-methoxy-2,3,6-trimethyl-benzyl alcohol 17.4 g of sodium salt of benzenesulfinic acid, 20.0 ml of isopropanol and 30.0 ml of glacial acetic acid are heated under reflux in a nitrogen atmosphere for 16 hours. After cooling, the reaction mixture is mixed in portions with 200 ml of water and neutralized by adding sodium bicarbonate. The organic phase is separated off, washed several times with a 5% aqueous sodium hydrogen carbonate solution, dried over sodium sulfate and evaporated under reduced pressure. The remaining l- (phenylsulfonyl) methyl-4-methoxy-2,3,6-trimethylbenzene shows the following I — R bands: 1592, 1580, 1302, 1149, 1118 cm-1.
B. 1,08 g 4-Methoxy-2,3,6-trimethyl-benzylchlorid, 1,67 g 8-(Phenyl-sulfonyl)-3,7-dimethyl-octa-2,4,6-trien-l-säure-äthylester und 10 ml Dimethylformamid werden auf 0° C gekühlt und mit 0,3474 g festem Natriumäthanolat versetzt. Das Reaktionsgemisch wird 30 Minuten bei Raumtemperatur gerührt, danach auf Eis gegossen und nach Zugabe von 2n Salzsäure mit Äther extrahiert. Der Ätherextrakt wird mit Wasser neutral gewaschen, über Natriumsulfat getrocknet und unter vermindertem Druck eingedampft. Der zurückbleibende 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-8-(phenylsulfonyl)-3,7-dimethyl-nona-2,4,6-trien-l-säureäthylester wird, wie unter A beschrieben, unter Abspaltung von Benzolsulfinsäure und unter Ausbildung einer zusätzlichen Kohlenstoff-Kohlenstoff-Bindung in den gewünschten 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-säureäthylester [Fp. 104—105° C] umgewandelt. B. 1.08 g of 4-methoxy-2,3,6-trimethyl-benzyl chloride, 1.67 g of 8- (phenyl-sulfonyl) -3,7-dimethyl-octa-2,4,6-triene-l- Acid ethyl ester and 10 ml of dimethylformamide are cooled to 0 ° C. and 0.3474 g of solid sodium ethanolate are added. The reaction mixture is stirred for 30 minutes at room temperature, then poured onto ice and extracted with ether after addition of 2N hydrochloric acid. The ether extract is washed neutral with water, dried over sodium sulfate and evaporated under reduced pressure. The remaining 9- (4-methoxy-2,3,6-trimethyl-phenyl) -8- (phenylsulfonyl) -3,7-dimethyl-nona-2,4,6-triene-l-acidic acid ethyl ester is as described under A described, with elimination of benzenesulfinic acid and with the formation of an additional carbon-carbon bond in the desired 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6 , 8-tetraen-1-acid ethyl ester [mp. 104-105 ° C].
Der als Ausgangsverbindung eingesetzte 8-(Phenyl-sulphonyl)-3,7-dimethyl-octa-2,4,6-trien-l-säureäthylester kann z. B. wie folgt hergestellt werden: The 8- (phenylsulfonyl) -3,7-dimethyl-octa-2,4,6-triene-l-acidic acid ethyl ester used as the starting compound can e.g. B. can be produced as follows:
8,5 g 8-Brom-3,7-dimethyl-octa-2,4,6-trien-l-säureäthyl-ester werden in 95 ml Dimethylsulfoxyd gelöst. Die Lösung wird unter Stickstoff in der Kälte mit 0,45 g Natriumsalz der Benzolsulfinsäure versetzt. Das Gemisch wird 1 Stunde bei Raumtemperatur gerührt, danach auf Eis gegossen und mit Äther extrahiert. Der Ätherextrakt wird mit Wasser gewaschen, über Natriumsulfat getrocknet und unter vermindertem Druck eingedampft. Der zurückbleibende 8-(Phenyl-sulfonyl)-3,7-dimethyl-octa-2,4,6-trien-l-säureäthylester schmilzt bei 114-115 °C. 8.5 g of 8-bromo-3,7-dimethyl-octa-2,4,6-triene-l-acidic acid ethyl ester are dissolved in 95 ml of dimethyl sulfoxide. The solution is mixed with nitrogen in the cold with 0.45 g of sodium salt of benzenesulfinic acid. The mixture is stirred at room temperature for 1 hour, then poured onto ice and extracted with ether. The ether extract is washed with water, dried over sodium sulfate and evaporated under reduced pressure. The remaining 8- (phenylsulfonyl) -3,7-dimethyl-octa-2,4,6-triene-l-acidic acid ester melts at 114-115 ° C.
Der im Beispiel 1 erhaltene Ester kann wie folgt in die freie Säure umgewandelt werden: The ester obtained in Example 1 can be converted into the free acid as follows:
116,7 g 9-(4-Methoxy-2,3,6-trimethyl-phenyI)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure-äthylester werden in 2000 ml abs. Äthanol eingetragen und mit einer Lösung von 125,8 g Kaliumhydroxyd in 195 ml Wasser versetzt. Das Gemisch wird unter Stickstoffbegasung 30 Minuten zum Sieden erhitzt, danach abgekühlt, in 101 Eiswasser eingetragen und nach Zugabe von ca. 240 ml konz. Salzsäure [pH 2-4] erschöpfend mit insgesamt 9 1 Methylenchlorid extrahiert. Der Extrakt wird mit etwa 6 1 Wasser neutral gewaschen, über Calciumchlorid getrocknet und unter vermindertem Druck eingedampft. Der Rückstand wird in 700 ml Hexan aufgenommen. Die ausfallende 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure schmilzt bei 228-230° C. 116.7 g of ethyl 9- (4-methoxy-2,3,6-trimethylphenyI) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid are dissolved in 2000 ml of abs . Ethanol entered and mixed with a solution of 125.8 g of potassium hydroxide in 195 ml of water. The mixture is heated to boiling under nitrogen gassing for 30 minutes, then cooled, introduced into 101 ice water and, after adding about 240 ml of conc. Hydrochloric acid [pH 2-4] extracted exhaustively with a total of 9 1 methylene chloride. The extract is washed neutral with about 6 liters of water, dried over calcium chloride and evaporated under reduced pressure. The residue is taken up in 700 ml of hexane. The precipitated 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid melts at 228-230 ° C.
Gemäss Beispiel 1 erhält man According to Example 1, one obtains
— aus l-(Phenyl-sulfonyl)-methyl-4-methoxy-2,3,6-trimethyl- - from l- (phenylsulfonyl) methyl-4-methoxy-2,3,6-trimethyl-
benzol und 8-Brom-3,7-dimethyl-octa-2,4,6-trien-l-säurebutylester benzene and 8-bromo-3,7-dimethyl-octa-2,4,6-triene-l-acidic acid butyl ester
— den 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurebutylester, Fp.: 80-81°C. nona-2,4,6,8-tetraen-1-acid butyl ester, m.p .: 80-81 ° C.
— aus l-(Phenyl-sulfonyl)-methyl-4-methoxy-2,3,6-trimethyl- - from l- (phenylsulfonyl) methyl-4-methoxy-2,3,6-trimethyl-
benzol und l-Acetoxy-8-brom-3,7-dimethyl-octa-2,4,6-trien benzene and l-acetoxy-8-bromo-3,7-dimethyl-octa-2,4,6-triene
— das l-Acetoxy-8-(4-methoxy-2,3,6-trimethyl-phenyl)- - the l-acetoxy-8- (4-methoxy-2,3,6-trimethyl-phenyl) -
3,7-dimethyl-nona-2,4,6,8-tetraen [Öl] 3,7-dimethyl-nona-2,4,6,8-tetraene [oil]
— aus l-(Phenyl-sulfonyl)-methyl-4-äthoxy-2,3,6-trimethyl- - from l- (phenylsulfonyl) methyl-4-ethoxy-2,3,6-trimethyl-
benzol und 8-Brom-3,7-dimethyl-octa-2,4,6-trien-l-säureäthylester benzene and 8-bromo-3,7-dimethyl-octa-2,4,6-triene-l-acidic acid ethyl ester
— den 9-(4-Äthoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-ethoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säureäthylester, Fp.: 96-97°C. ethyl nona-2,4,6,8-tetraen-l, m.p .: 96-97 ° C.
— aus l-(Phenyl-sulfonyl)-methyl-4-methoxy-2,3,5,6-tetra- - from l- (phenylsulfonyl) methyl-4-methoxy-2,3,5,6-tetra-
methyl-benzol und 8-Brom-3,7-dimethyl-octa-2,4,6-trien-l-säurebutylester methyl benzene and 8-bromo-3,7-dimethyl-octa-2,4,6-triene-l-acid acid butyl ester
— den 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - the 9- (4-methoxy-2,3,5,6-tetramethyl-phenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säurebutylester [Öl] und daraus methyl-nona-2,4,6,8-tetraen-l-acidic acid butyl ester [oil] and therefrom
— die 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - the 9- (4-methoxy-2,3,5,6-tetramethylphenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säure, Fp.: 230 bis 233 °C. methyl-nona-2,4,6,8-tetraen-l-acid, mp .: 230 to 233 ° C.
Beispiel 2 Example 2
60 g 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure werden in 1000 ml Aceton gelöst. Die Lösung wird nach Zugabe von 128 g Methyljodid und 128 g Kaliumcarbonat unter Stickstoffbegasung 16 Stun5 60 g of 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid are dissolved in 1000 ml of acetone. After the addition of 128 g of methyl iodide and 128 g of potassium carbonate, the solution is 16 hours under nitrogen gas
10 10th
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
50 50
55 55
60 60
65 65
den bei 55-60° C gerührt und anschliessend unter vermindertem Druck eingedampft. Der Rückstand wird in 1300 ml Petroläther [Siedepunkt 80-105° C] gelöst. Der bei -20° C auskristallisierende 9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säuremethylester schmilzt bei 98-99° C. which is stirred at 55-60 ° C and then evaporated under reduced pressure. The residue is dissolved in 1300 ml of petroleum ether [boiling point 80-105 ° C]. The 9- (4-methoxy-2,3,6-trimethylphenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acidic acid methyl ester, which crystallizes out at -20 ° C., melts at 98-99 ° C.
In analoger Weise erhält man One obtains in an analogous manner
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure und Äthyljodid den 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säureäthylester, Fp.: 104 bis 105°C; nona-2,4,6,8-tetraen-l-acid and ethyl iodide den 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6, 8-tetraen-l-acidic acid ester, mp .: 104 to 105 ° C;
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure und Isopropyljodid nona-2,4,6,8-tetraen-l-acid and isopropyl iodide
- den 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säureisopropylester [Öl]; isopropyl nona-2,4,6,8-tetraen-1-oil [oil];
- aus 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - from 9- (4-methoxy-2,3,5,6-tetramethylphenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säure und Äthyljodid methyl-nona-2,4,6,8-tetraen-l-acid and ethyl iodide
- den 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - the 9- (4-methoxy-2,3,5,6-tetramethyl-phenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säureäthylester, Fp.: 105—106°C; methyl nona-2,4,6,8-tetraen-l-acidic acid ester, m.p .: 105-106 ° C;
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure und Diäthylaminoäthylchlorid nona-2,4,6,8-tetraen-l-acid and diethylaminoethyl chloride
- den 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure-2-(diäthylamino)-äthyl-ester [hellgelbes Öl]; nona-2,4,6,8-tetraen-l-acid-2- (diethylamino) ethyl ester [light yellow oil];
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure und /3-Picolinchlorid nona-2,4,6,8-tetraen-l-acid and / 3-picoline chloride
- den 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure-(3-pyridyI)-methylester, Fp.: 113-114°C. nona-2,4,6,8-tetraen-l-acid- (3-pyridyl) methyl ester, m.p .: 113-114 ° C.
Beispiel 3 Example 3
28,6 g 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säure werden in 300 ml Benzol eingetragen und unter Stickstoffbegasung mit 12 g Phosphortri-chlorid versetzt. Das Benzol wird anschliessend unter vermindertem Druck abdestilliert. Das zurückbleibende 9-(4-Meth-oxy-2,4,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säurechlorid wird in 1200 ml Äther gelöst. Die Lösung wird bei —33 ° C in 500 ml flüssiges Ammoniak eingetropft und 3 Stunden gerührt. Das Reaktionsgemisch wird danach mit 500 ml Äther verdünnt und ohne Kühlung 12 Stunden weitergerührt, wobei das Ammoniak verdampft. Der Rückstand wird in 10 1 Methylenchlorid gelöst. Die Lösung wird 2mal mit 3 1 Wasser gewaschen, über Natriumsulfat ge616 135 28.6 g of 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid are introduced into 300 ml of benzene and 12 g of phosphorus tri-chloride were added while gassing with nitrogen. The benzene is then distilled off under reduced pressure. The remaining 9- (4-meth-oxy-2,4,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-1-acid chloride is dissolved in 1200 ml of ether. The solution is dropped into 500 ml of liquid ammonia at -33 ° C. and stirred for 3 hours. The reaction mixture is then diluted with 500 ml of ether and stirred for 12 hours without cooling, the ammonia evaporating. The residue is dissolved in 10 1 methylene chloride. The solution is washed twice with 3 l of water, over sodium sulfate ge616 135
trocknet und unter vermindertem Druck eingedampft. Das zurückbleibende 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-l-säureamid schmilzt nach dem Umkristallisieren aus Äthanol bei 207-209° C. dries and evaporated under reduced pressure. The remaining 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-nona-2,4,6,8-tetraen-l-acid amide melts after recrystallization from ethanol at 207- 209 ° C.
In analoger Weise erhält man One obtains in an analogous manner
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurechlorid und Äthylamin nona-2,4,6,8-tetraen-l-acid chloride and ethylamine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säureäthylamid; Fp.: 179 bis 180°C; nona-2,4,6,8-tetraen-l-acid ethylamide; Mp: 179-180 ° C;
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-1 -säurechlorid und Diäthylamin nona-2,4,6,8-tetraen-1-acid chloride and diethylamine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurediäthylamid; Fp.: 105 bis 106°C; nona-2,4,6,8-tetraen-1-acid diethylamide; Mp 105-106 ° C;
- aus 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - from 9- (4-methoxy-2,3,5,6-tetramethylphenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säurechlorid und Äthylamin methyl-nona-2,4,6,8-tetraen-l-acid chloride and ethylamine
- das 9-(4-Methoxy-2,3,5,6-tetramethyl-phenyl)-3,7-di- - the 9- (4-methoxy-2,3,5,6-tetramethyl-phenyl) -3,7-di-
methyl-nona-2,4,6,8-tetraen-l-säureäthylamid, Fp.: 200—201°C; methyl-nona-2,4,6,8-tetraen-l-acid ethylamide, m.p .: 200-201 ° C;
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurechlorid und Morpholin nona-2,4,6,8-tetraen-1-acid chloride and morpholine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säuremorpholid. nona-2,4,6,8-tetraen-l-acid morpholide.
Beispiel 4 Example 4
In Analogie zu der in Beispiel 3 beschriebenen Arbeitsweise können hergestellt werden: In analogy to the procedure described in Example 3, the following can be produced:
- aus 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - from 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurechlorid, nona-2,4,6,8-tetraen-l-acid chloride,
durch Umsetzen mit Methylamin, by reacting with methylamine,
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säuremethylamid; Fp.: 206°C. nona-2,4,6,8-tetraen-1-acid methylamide; Mp .: 206 ° C.
durch Umsetzen mit Isopropylamin by reacting with isopropylamine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säureisopropylamid; Fp.: 200°C. nona-2,4,6,8-tetraen-l-acid isopropylamide; Mp .: 200 ° C.
durch Umsetzen mit n-Butylamin by reacting with n-butylamine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säure-n-butylamid; Fp.: 178°C. nona-2,4,6,8-tetraen-l-acid-n-butylamide; Mp: 178 ° C.
durch Umsetzen mit Hexylamin by reaction with hexylamine
- das 9-(4-Methoxy-2,3,6-trimethyl-phenyl)-3,7-dimethyl- - the 9- (4-methoxy-2,3,6-trimethyl-phenyl) -3,7-dimethyl-
nona-2,4,6,8-tetraen-l-säurehexylamid; Fp.: 157—158°C. nona-2,4,6,8-tetraen-1-acid hexylamide; Mp: 157-158 ° C.
7 7
5 5
10 10th
15 15
20 20th
25 25th
30 30th
35 35
40 40
45 45
50 50
S S
Claims (11)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH460373A CH585166A5 (en) | 1973-03-30 | 1973-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CH616135A5 true CH616135A5 (en) | 1980-03-14 |
Family
ID=4279174
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH460373A CH585166A5 (en) | 1973-03-30 | 1973-03-30 | |
CH171076A CH616134A5 (en) | 1973-03-30 | 1976-02-12 | Process for the preparation of novel polyene compounds |
CH171376A CH616136A5 (en) | 1973-03-30 | 1976-02-12 | Process for the preparation of novel polyene compounds |
CH171176A CH616135A5 (en) | 1973-03-30 | 1976-02-12 | Process for the preparation of polyene compounds |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH460373A CH585166A5 (en) | 1973-03-30 | 1973-03-30 | |
CH171076A CH616134A5 (en) | 1973-03-30 | 1976-02-12 | Process for the preparation of novel polyene compounds |
CH171376A CH616136A5 (en) | 1973-03-30 | 1976-02-12 | Process for the preparation of novel polyene compounds |
Country Status (32)
Country | Link |
---|---|
JP (1) | JPS5724333B2 (en) |
AR (1) | AR207004A1 (en) |
AT (1) | AT340397B (en) |
AU (1) | AU472475B2 (en) |
BE (1) | BE813002A (en) |
BR (1) | BR7402525D0 (en) |
CA (1) | CA1030975A (en) |
CH (4) | CH585166A5 (en) |
CU (1) | CU34050A (en) |
DD (1) | DD111368A5 (en) |
DE (1) | DE2414619C2 (en) |
DK (1) | DK155043C (en) |
ES (1) | ES424750A1 (en) |
FI (1) | FI62280C (en) |
FR (1) | FR2223037B1 (en) |
GB (2) | GB1468402A (en) |
HK (1) | HK28780A (en) |
HU (1) | HU172655B (en) |
IE (1) | IE39098B1 (en) |
IL (1) | IL44368A (en) |
KE (1) | KE3047A (en) |
LU (2) | LU69733A1 (en) |
MX (1) | MX152550A (en) |
MY (1) | MY8100064A (en) |
NL (2) | NL161429C (en) |
NO (2) | NO143426C (en) |
PH (1) | PH13081A (en) |
PL (1) | PL96105B1 (en) |
SE (1) | SE419752B (en) |
SU (1) | SU613718A3 (en) |
YU (1) | YU40253B (en) |
ZA (1) | ZA741580B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3444051A1 (en) * | 1983-12-08 | 1985-06-13 | F. Hoffmann-La Roche & Co Ag, Basel | NEW RETINOIDS |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH604705A5 (en) * | 1974-09-24 | 1978-09-15 | Hoffmann La Roche | |
CH619437A5 (en) * | 1975-08-22 | 1980-09-30 | Hoffmann La Roche | Process for the preparation of polyene compounds. |
US4335248A (en) | 1975-11-14 | 1982-06-15 | Hoffmann-La Roche Inc. | Fluorinated polyenes |
US4169100A (en) * | 1975-11-14 | 1979-09-25 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4137246A (en) * | 1976-09-13 | 1979-01-30 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4266073A (en) * | 1975-11-14 | 1981-05-05 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4395575A (en) | 1975-11-14 | 1983-07-26 | Hoffmann-La Roche, Inc. | 5(Halophenyl)-2-fluoro-pentadienals |
US4299995A (en) | 1979-05-10 | 1981-11-10 | Hoffmann-La Roche Inc. | Fluorinated polyenes |
CH624373A5 (en) * | 1975-11-14 | 1981-07-31 | Hoffmann La Roche | Process for the preparation of polyene compounds |
US4201727A (en) | 1976-11-14 | 1980-05-06 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4321209A (en) | 1975-11-14 | 1982-03-23 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4338253A (en) | 1975-11-14 | 1982-07-06 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
US4375563A (en) | 1975-11-14 | 1983-03-01 | Hoffmann-La Roche Inc. | Fluorinated aromatic polyenes |
CA1111441A (en) | 1976-12-20 | 1981-10-27 | Werner Bollag | Polyene compounds |
US4200647A (en) * | 1977-12-21 | 1980-04-29 | Hoffmann-La Roche Inc. | Vitamin A compositions to treat rheumatic disease |
US4642318A (en) * | 1982-11-17 | 1987-02-10 | Klaus Wolff | Method for decreasing radiation load in PUVA therapy |
ZA854828B (en) * | 1984-07-27 | 1986-03-26 | Hoffmann La Roche | Phenyl nonatetraenoic acid derivatives |
US5250562A (en) * | 1988-02-24 | 1993-10-05 | Hoffmann-La Roche Inc. | Stilbene derivatives |
JPH10158192A (en) * | 1996-10-03 | 1998-06-16 | Eisai Co Ltd | Medicine composition for treating graft-versus-host disease (gvhd) and for suppressing graft rejection in organ transplantation |
JP4584384B2 (en) * | 1999-09-28 | 2010-11-17 | 扶桑薬品工業株式会社 | New antitumor agent |
DE102008002302A1 (en) | 2007-06-13 | 2008-12-18 | Basf Se | Preparing etretinate, useful to treat severe psoriasis and ichthyosis vulgaris, comprises reacting acitretin with active reagent e.g. 1,1'-carbonyldiimidazole, followed by reacting with ethanol and/or alkali or alkaline earth ethanolate |
WO2009086490A2 (en) * | 2007-12-28 | 2009-07-09 | Bridgestone Corporation | Hydroxyaryl functionalized polymers |
-
1973
- 1973-03-30 CH CH460373A patent/CH585166A5/xx active Protection Beyond IP Right Term
-
1974
- 1974-01-01 AR AR252831A patent/AR207004A1/en active
- 1974-03-07 IL IL44368A patent/IL44368A/en unknown
- 1974-03-11 ZA ZA00741580A patent/ZA741580B/en unknown
- 1974-03-12 AU AU66566/74A patent/AU472475B2/en not_active Expired
- 1974-03-25 PH PH15656A patent/PH13081A/en unknown
- 1974-03-25 IE IE643/74A patent/IE39098B1/en unknown
- 1974-03-26 DE DE2414619A patent/DE2414619C2/en not_active Expired
- 1974-03-28 DD DD177523A patent/DD111368A5/xx unknown
- 1974-03-28 FR FR7410832A patent/FR2223037B1/fr not_active Expired
- 1974-03-28 SU SU742008955A patent/SU613718A3/en active
- 1974-03-28 LU LU69733*A patent/LU69733A1/xx active Protection Beyond IP Right Term
- 1974-03-29 AT AT260174A patent/AT340397B/en active Protection Beyond IP Right Term
- 1974-03-29 YU YU883/74A patent/YU40253B/en unknown
- 1974-03-29 JP JP3481374A patent/JPS5724333B2/ja not_active Expired
- 1974-03-29 NL NL7404324.A patent/NL161429C/en active Protection Beyond IP Right Term
- 1974-03-29 NO NO741144A patent/NO143426C/en unknown
- 1974-03-29 CA CA196,337A patent/CA1030975A/en not_active Expired
- 1974-03-29 BR BR2525/74A patent/BR7402525D0/en unknown
- 1974-03-29 CU CU7434050A patent/CU34050A/en unknown
- 1974-03-29 FI FI981/74A patent/FI62280C/en active Protection Beyond IP Right Term
- 1974-03-29 BE BE142589A patent/BE813002A/en not_active IP Right Cessation
- 1974-03-29 PL PL1974169924A patent/PL96105B1/en unknown
- 1974-03-29 GB GB918576A patent/GB1468402A/en not_active Expired
- 1974-03-29 HU HU73HO00001662A patent/HU172655B/en unknown
- 1974-03-29 MX MX150257A patent/MX152550A/en unknown
- 1974-03-29 DK DK176174A patent/DK155043C/en active Protection Beyond IP Right Term
- 1974-03-29 GB GB1401674A patent/GB1468401A/en not_active Expired
- 1974-03-29 SE SE7404312A patent/SE419752B/en not_active IP Right Cessation
- 1974-03-29 ES ES424750A patent/ES424750A1/en not_active Expired
-
1976
- 1976-02-12 CH CH171076A patent/CH616134A5/en not_active IP Right Cessation
- 1976-02-12 CH CH171376A patent/CH616136A5/en not_active IP Right Cessation
- 1976-02-12 CH CH171176A patent/CH616135A5/en not_active IP Right Cessation
-
1980
- 1980-05-03 KE KE3047A patent/KE3047A/en unknown
- 1980-05-22 HK HK287/80A patent/HK28780A/en unknown
-
1981
- 1981-12-30 MY MY64/81A patent/MY8100064A/en unknown
-
1993
- 1993-06-16 LU LU88313C patent/LU88313I2/en unknown
- 1993-06-17 NL NL930081C patent/NL930081I2/en unknown
-
1994
- 1994-07-07 NO NO1994004C patent/NO1994004I1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3444051A1 (en) * | 1983-12-08 | 1985-06-13 | F. Hoffmann-La Roche & Co Ag, Basel | NEW RETINOIDS |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH616135A5 (en) | Process for the preparation of polyene compounds | |
DE2819213C2 (en) | ||
EP0253302B1 (en) | Tetrahydronaphthalène and indane derivatives, their synthesis and application in pharmaceutical preparations | |
DE3715809A1 (en) | TETRAHYDRONAPHTHALINE DERIVATIVES | |
DE2440606A1 (en) | POLYENE COMPOUNDS | |
DE2437607A1 (en) | POLYENE COMPOUNDS | |
EP0058370B1 (en) | Tetrahydronaphthalene and indan compounds, their production and pharmaceutical preparations | |
DE3202100A1 (en) | SUBSTITUTED 4-HYDROXYANILIDES, ITS PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
DE2305267A1 (en) | NEW SULPHONES DERIVED FROM 1,5-DIMETHYLHEXADIEN (1,5) -YLENE | |
DE2356655C3 (en) | Substituted phenoxy-α-methylpropionic acid derivatives, process for their preparation and pharmaceuticals containing them | |
EP0004680A2 (en) | Derivative nonatetraenoic acid and pharmaceutical compositions | |
DE2542612C2 (en) | ||
DE2440525A1 (en) | POLYENE COMPOUNDS | |
CH629768A5 (en) | METHOD FOR PRODUCING 5,6-CIS AND 5,6-TRANS-10,19-DIHYDROVITAMINE D DERIVATIVES. | |
DE2756652C2 (en) | ||
DE2651979C2 (en) | 9-Phenyl-3,7-dimethyl-2,4,6,8-nonatetraene compounds, process for their preparation and their use | |
AT340902B (en) | PROCESS FOR PRODUCING NEW POLYENE COMPOUNDS | |
DE3202065A1 (en) | Substituted N-(5-tetrazolyl)benzamides, the preparation thereof and pharmaceutical compositions containing these | |
AT392780B (en) | METHOD FOR PRODUCING NEW ACID DERIVATIVES | |
CH611872A5 (en) | Process for the preparation of polyene compounds | |
CH586673A5 (en) | Dihydro-vitamin A derivs. and analogues - with antineoplastic and dermatological props | |
KR820000180B1 (en) | Process for preparation of polyene compounds | |
AT362776B (en) | METHOD FOR PRODUCING NEW STYLE DERIVATIVES AND THEIR SALTS | |
DE2132032A1 (en) | Polyene compounds | |
DE2542601A1 (en) | POLYENE COMPOUND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUE | Assignment |
Owner name: F. HOFFMANN-LA ROCHE AG |
|
PL | Patent ceased |